SwitzerlandSwitzerland

Switzerland

16.09.2003

Zürich - The new marketing initiative ‚Swiss Biotech' was formed earlier this year (www.swissbiotech.com). The goal of the initiative is to further the positioning of the Biotechnology sector of Switzerland nationally and internationally. It was started to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of Swiss biotechnology including research, education, economics, finance and industry. Among the founding members are the established regional life science clusters, Basel, Zürich and the Geneva lake region.

SwitzerlandSwitzerland

12.04.2011

Zurich – Swiss Novartis AG has discontinued a Phase III head-to-head comparison of Tasigna (nilotinib) with the company’s US-$4 million blockbuster Glivec (imatinib) as first-line treatment of gastrointestinal stromal tumours...

SwitzerlandSwitzerland

06.04.2011

Basel – The Swiss biotech industry has shown itself to be vigorously robust during the economic crisis and has kept revenues and its number of employees stable. According to the Swiss Biotech Report 2011, which was published...

SwitzerlandSwitzerland

10.03.2011

Basel – Swiss Novartis AG’s effort to get the first ever US approval for two doses of a bronchodilator has failed. Yesterday, an FDA panel recommended the 75 microgram (mcg) dose of the firm’s potential US$ 5bn blockbuster...

SwitzerlandSwitzerland

18.02.2011

Muttenz/Munich – Swiss chemistry specialist Clariant AG had made a 2bn bid for Munich-based catalysis and adsorbents specialist Süd-Chemie aimed at taking over the controlling majority from two groups of stockholders. The...

SwitzerlandSwitzerland

08.02.2011

Zurich – Researchers headed by Wilhelm Krek from ETH Zurich have presented a new strategy for biomarker-based diagnosis of prostate cancer. The researchers said their two-step approach is generally suitable for discovery of serum...

SwitzerlandSwitzerland

06.02.2011

Zurich – In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG. Among other assets, the agreement gives Biogen the worldwide rights to three...

SwitzerlandSwitzerland

06.02.2011

Zug – Canadian Valeant Pharmaceuticals International Inc will acquire branded generics and OTC company Pharma­Swiss S.A. for EUR350m, plus up to EUR30m in milestones. Valeant said the acquisition will strengthen its position in...

Displaying results 51 to 60 out of 276

< Previous 51-60 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/5/article/switzerland-27.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%
  • ADDEX4.00 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%

TOP

  • SANTHERA82.95 CHF20.4%
  • LONZA101.10 CHF6.1%
  • MAGFORCE6.50 EUR5.7%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.10 EUR-24.5%
  • VITA 343.96 EUR-18.4%

TOP

  • SANTHERA82.95 CHF3758.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR195.2%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-68.1%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 22.08.2014


Current issue

All issues

Product of the week

Products